Phase 2 Breast Cancer Trial, Recruiting NCT06749210 Sponsor: Ohio State University Comprehensive Cancer Center Condition: Breast Cancer
Back to Breast Cancer

Phase 2 Breast Cancer Trial, Recruiting

NCT06749210
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with breast cancer at any stage, including cancer that has spread to other parts of the body.
  • People who finished a chemotherapy treatment containing taxanes (a type of chemotherapy drug) at least 3 months ago, with no upper time limit on how long ago it was completed.
  • People who are currently experiencing nerve pain or numbness caused by chemotherapy (based on their own report of symptoms).
  • People whose balance test results suggest they may be at risk of falling.
  • People who are able to understand and follow instructions related to the study tests and treatments.

Who may not be able to join:

  • People who have a pre-existing condition affecting the inner ear or balance system (vestibular dysfunction).
  • People with poorly controlled diabetes, indicated by a blood sugar marker (HbA1c) of 8 or higher.
  • People who are unable to walk independently, although the use of walking aids or prosthetic limbs is permitted.
  • People with significant hearing loss, specifically less than 10% hearing in both ears.
  • People whose treating cancer doctor advises against taking part in physical activity due to another medical condition, such as a herniated disc or unstable spread of cancer to the bones.
  • People who are currently receiving a therapy that involves physical activity, such as physiotherapy or occupational therapy — though enrolment may be considered once that therapy has finished, if eligibility criteria are still met at that time.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Lise B Worthen-Chaudhari, PhD, MFA, CMES, Ohio State University

Phone: (1) + 614-293-6281

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Ohio State University Comprehensive Cancer Center
Registry
ClinicalTrials.gov
Start date
19 February 2025
Est. completion
15 August 2029

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Patient-Reported Outcome (PRO) - CIN sensation; Dual-task function

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov